Background
==========

Chronic pain is a major health problem. Therefore, providing better treatment and better methods for preventing chronic pain is of clinical importance. In particular neuropathic pain, which has a higher morbidity, is severely debilitating, and is largely resistant to treatments. However, the underlying mechanisms of neuropathic pain are still unknown. Several mechanisms have been shown to be involved in the initiation and propagation of neuropathic pain, including increased excitability and reduced thresholds of primary sensory neurons, altered spinal cord synaptic processing, loss of inhibitory interneurons and modifications of brain stem input to the spinal cord \[[@B1]-[@B3]\].

The Notch signaling pathway is a highly conserved pathway in evolution, which is involved in many physiological and pathological processes, such as vasculogenesis, immunological processes, development, learning and memory, and tumor formation \[[@B4]-[@B7]\]. Notch is one of the cell-surface receptors that regulate cell-fate decision in the developing nervous system. Ligands such as Delta and Jagged bind to Notch receptors, resulting in proteolytic cleavage of Notch into two sections: an extracellular domain and a transmembrane domain. The latter cleavage is completed by the γ-secretase enzyme and ADAM, resulting in the release of a Notch intracellular domain (NICD) that translocates to the nucleus, where it regulates transcription \[[@B8]\]. Some findings suggest that activation of Notch signaling can contribute to neuronal death, generation and activation of microglial cells and astrocytes, inhibition of neurite growth \[[@B9]-[@B11]\], more dendritic branching \[[@B12]\], differentiation of oligodendrocyte progenitors and demyelination in both the peripheral nervous system \[[@B13]\] and the CNS (central nervous system) \[[@B14]\].

Recent studies have demonstrated that activation of the Notch signaling pathway potentiates synaptic transmission in the hippocampus \[[@B15]\]. The role of the Notch signaling pathway in sensory sensation, particularly in nociceptive transmission remains unclear. Therefore, this study observed the effect of the Notch signaling pathway on nociceptive responses induced by nerve injury.

Results and discussion
======================

Our present study shows that NICD expression in the rat sciatic nerve and dorsal horn of the spinal cord is markedly increased following peripheral nerve injury. Seven days after induction of the unilateral CCI (Sciatic Nerve Chronic Constriction Injury Model) model, immunoblot analyses showed that NICD protein levels in the dorsal horn of the spinal cord increased to \~168.3% of the control (Figure [1](#F1){ref-type="fig"}A). NICD protein levels in the sciatic nerve increased to \~171.4% of the control (Figure [1](#F1){ref-type="fig"}B), and the density of the NICD-immunoreactive product in the spinal cord was increased significantly in laminas I-II at 7 days after nerve injury in the CCI model (Figure [1](#F1){ref-type="fig"}C). However, both NICD mRNA and protein levels in rat DRG neurons were not altered significantly following peripheral nerve injury (Figure [2](#F2){ref-type="fig"}A-C). Co-immunostaining of NICD and Substance P, or IB4, indicated that NICD partially co-localized with peptidergic small DRG neurons (Figure [2](#F2){ref-type="fig"}D).

![**Change in expression of NICD in the sciatic nerve and dorsal horn of the spinal cord in control and CCI model rats.** (**A**) Immunoblotting showed the expression of NICD in the dorsal horn of the spinal cord. NICD increased after nerve injury (CCI model) (n = 3). (**B**) Immunoblotting showing the expression of NICD in the sciatic nerve. NICD increased after nerve injury (CCI model) (n = 3). (**C**) Immunostaining showed that the expression of NICD was significantly increased after nerve injury (CCI model). Scale bar, 100 μm.](1756-6606-5-23-1){#F1}

![**The change in expression of NICD in DRG neurons in control and CCI model rats.** (**A**) Immunostaining showing the expression of NICD in the DRG. NICD was present in small neurons in the DRG, and nerve injury did not induce significant change. Scale bar, 100 μm. (**B**) RT-PCR revealed Notch1 expression in DRG tissue, while nerve injury did not induce a significant change. (**C**) Immunoblotting showed that in the rat DRG, the levels of NICD did not markedly change after nerve injury (CCI model) (n = 3). The data represents three independent experiments. (**D**) Immunostaining revealed that NICD co-localized with substance P, but did not co-localize with IB4 in the DRG. Scale bar, 100 μm.](1756-6606-5-23-2){#F2}

To test whether nerve injury-induced NICD expression contributes to pain hypersensitivity, DAPT, a γ-secretase enzyme inhibitor, was injected intrathecally (i.t.) before nerve injury. Spinal NICD expression levels decreased significantly 7 days after in the SNI model(P \< 0.05) (Figure [3](#F3){ref-type="fig"}A). We found that DAPT suppressed thermal hyperalgesia and mechanical allodynia induced by CCI (Figure [3](#F3){ref-type="fig"}B) and inhibited the mechanical allodynia induced by the SNI model in a dose-dependent manner (Figure [3](#F3){ref-type="fig"}C). Thus, the marked increase of NICD in the dorsal spinal cord could be an underlying mechanism for the development of neuropathic pain.

![**DAPT inhibits thermal hyperalgesia and mechanical allodynia induced by CCI and SNI.** (**A**) Immunostaining revealed that the increase of NICD expression in the spinal cord after nerve injury was significantly inhibited by injection with DAPT. Scale bar, 100 μm. (**B**) Intrathecal (i.t.) administration of DAPT inhibits thermal hyperalgesia and mechanical allodynia 7 days after CCI. (n = 10). (**C**) Intrathecal (i.t.) DAPT inhibits mechanical allodynia after SNI in a dose-dependent manner. \* *P* \< 0.05, \*\* *P* \< 0.01, \*\*\* *P* \< 0.01 versus SNI rats treated with vehicle (mean ± s.e.m., two-way ANOVA with a *post hoc* Bonferroni's test, n = 15).](1756-6606-5-23-3){#F3}

In this study, we found that NICD was upregulated in the sciatic nerve and spinal cord after nerve injury. DAPT, an inhibitor of a key enzyme in the Notch signaling pathway, reversed the thermal hyperalgesia and mechanical allodynia induced by nerve injury. We therefore speculate that the Notch signaling pathway is involved in the development and maintenance of neuropathic pain.

Recently, a number of studies have shown that Notch participates in synaptic plasticity, learning and memory in rodents \[[@B16]-[@B18]\], long-term memory formation in Drosophila \[[@B19]-[@B21]\], and locomotive behavior in C. elegans \[[@B22]\]. Decline of Notch1 expression by 50% (using an anti-sense strategy) resulted in reduced longterm potentiation (LTP) \[[@B18]\].

In our present study, we demonstrated that NICD is expressed in the DRG, sciatic nerve and spinal cord in adult rats, and that NICD was increased in the sciatic nerve and spinal cord after nerve injury, indicating its potential role in the development of neuropathic pain. On the other hand, although the change of NICD expression in the DRG was not statistically significant compared with the sciatic nerve and spinal cord, there was an increasing trend. Our results showed that expression of NICD in DRG neurons was upregulated from \~53% to \~61%, while western-blot results showed no apparent change in NICD protein levels after nerve injury. Therefore, we believe that NICD may be transported to the central terminals after production, so that the expression of NICD is upregulated in the spinal cord and sciatic nerve. Consistent with our results, some studies have shown that the Notch signaling pathway enhanced calcium influx in DRG neurons and also potentiated synaptic transmission in the hippocampus \[[@B15],[@B23]\]. In addition, in the spinal cord compression injury model, the expression of Notch1 increased after spinal cord injury \[[@B24]\]. These results indicated that the Notch signaling pathway is involved in nociceptive transmission in the spinal cord.

Conclusion
==========

In conclusion, activation of the Notch signaling pathway may contribute to the generation and development of neuropathic pain. The upregulation of NICD in the spinal cord after nerve injury is an important factor for the development of neuropathic pain, and inhibition of γ-secretase may be a potential therapeutic strategy for treating neuropathic pain.

Materials and methods
=====================

Animals
-------

Adult male Sprague--Dawley rats (Laboratory Animal Center of Fourth Military Medical University (FMMU), China) weighing 180--220 g, were used in the study. The animals were kept in plastic boxes at 22-26°C with free access to food and water. All rats were allowed to acclimatize to the housing facilities and were handled daily for at least 3 days. All experimental protocols and animal handling procedures were approved by the FMMU Animal Care and Use Committee and adhered to the guidelines for the ethical treatment of animals established by the International Association for the Study of Pain.

RT-PCR
------

Notch1 was identified in the rat DRG by RT-PCR using the following primers: 5'- TGAGATGCTCCCAGCCAAGT 3' and 5'- AGATGTATGAAGACTCAAAGGG -3'(5 min at 95°C, 30s at 95°C, 30s at 58°C, 30s at 68°C; 40cycle).

Immunoblotting
--------------

The DRG, sciatic nerve and spinal cord tissues were sonicated/homogenized and centrifuged. Thirty micro-grams of protein was extracted from the above preparations, and loaded and separated on a 10% (w/v) SDS-polyacrylamide gel. After transfer, blots were incubated overnight at 4°C with separately with NICD (1:1000; Abcam, London, UK) and GAPDH (1:10000; Chemicon, Temecula, CA, USA) primary antibodies. Blots were visualized using enhanced chemiluminescence (ECL; Roche, Basel, Switzerland). Quantification was based on 3 independent experiments. The ECL signal intensity of NICD versus GADPH was quantified using the NIH image program.

Immunostaining
--------------

Adult male rats were fixed with 4% (w/v) paraformaldehyde. For all experimental groups, 12 μm-thick sections of the fixed L4-5 DRG and L4-5 spinal cord segments were cut. The sections were processed with indirect immunofluorescent histochemistry. Antisera were diluted in phosphate buffered saline (PBS) containing 0.3% (v/v) Triton X-100 and 1% (w/v) bovine serum albumin. Briefly, the sections were incubated with a mixture of rabbit anti-NICD antibodies (1:500) overnight at 4°C. The sections were rinsed three times in PBS and then incubated with fluorescence-conjugated donkey anti--rabbit (1:100) and rhodamine-conjugated donkey anti-goat IgG (1:100; Jackson Immuno Research, West Grove, PA, USA) for 30 min at 37°C. After several rinses in PBS, the sections were placed under a Leica SP2 confocal microscope (Leica Microsystem, Heidelberg, Germany) and images were captured.

SNI model of neuropathic pain
-----------------------------

The left SNI model was performed as previously described \[[@B25]\]. Briefly,Under pentobarbital sodium anesthesia (40 mg/kg), an incision was made on the left side skin of the hind leg. The muscle and strands of the bicep femoris were separated to expose the sciatic nerve-trunk and carefully separate its three branches: tibial, common peroneal and sural nerves. After separation, double ligation of the tibial and common peroneal was performed using a 5.0 silk thread, and 2--3 mm of the nerves distal to the ligation were removed, taking care to avoid inducing any lesion, or stretching the intact sural nerve. The muscle and skin incisions were then closed separately. Sham surgery groups only underwent sciatic nerve-trunk exposure and exposure of their branches, but did not undergo ligation and transection. A skin incision was made to blind the observer during behavioral testing. Animals were habituated to the tester, the environment, and to the handling procedures before commencement of testing.

CCI model of neuropathic pain
-----------------------------

CCI of the sciatic nerve was used as a model of neuropathic pain, and was adapted to the mouse \[[@B26]\]. Briefly, under pentobarbital sodium anesthesia (40 mg/kg, intra-peritoneal injection), the left sciatic nerve was exposed by blunt dissection around the nerve proximal to the trifurcation and loosely ligated at four sites using a 4-0 chromic catgut suture (Jinhuan Medical Instruments Co., Ltd., Shanghai, China). The distance between the two adjacent ligatures was 1 mm. The wound was irrigated with saline (0.9% (w/v)) and closed in two layers with 4-0 silk (facial plane) and surgical skin staples. For the sham operation, the sciatic nerve was exposed but not ligated.

Intrathecal surgery and drug injection
--------------------------------------

The permanent intrathecal catheter (PE-10 polyethylene tube) was inserted through the gap between the T3 and T4 vertebrae and extended slowly to the subarachnoid space of the lumbar enlargement (L4 and L5 segments) under sodium pentobarbital (40 mg/kg, intraperitoneal (i.p.) anesthesia. The catheter was filled with sterile NS(Normal Saline) (approximately 4 μL), and the outer end was plugged in the skin to avoid the paws. The cannulated rats were allowed to recover for 3-4 days. Excluding rats with any neurological deficits, at the end of each experiment, pontamine sky blue was injected via the i.t. catheter to prove its effectiveness. DAPT (Sigma, St. Louis, MO, USA), a potent inhibitor of Notch signaling pathway activation, was freshly dissolved daily in dimethy sulphoxide (DMSO) to a concentration of 50 mM. Drug or vehicle (DMSO) was injected over a period of 1 min via the catheter at a volume of 10 μL, followed by 5 μL NS for flushing, and all drugs were injected once 30 min before surgery.

Behavioral testing
------------------

Animals were housed in plastic boxes and allowed to acclimatize for at least 24 h before testing commenced. This allowed animals to become familiarized with the handling and environment. Baseline assessments of nociceptive sensitivity were taken for all animals 24 h before surgery. All behavioral pain tests were conducted at the same time each day, between 10.00 AM and 1.00 PM.

Thermal hyperalgesia testing
----------------------------

Animals were placed in a clear glass cage with a glass floor and allowed to acclimatize for 30 min. For the once pre- and post-drug experiment, a beam of radiant heat was applied to the middle of the plantar surface of the operation-lateral paws on days 7, 14, and 21 after drug or vehicle administration. Withdrawal latency was recorded. Radiant heat was adjusted so that the baseline latency was 20- 25 s. The cutoff time was 30 s. The latency was examined at least three times, with at least 10 min between the two consecutive stimuli on the same paw.

Mechanical allodynia testing
----------------------------

For the once pre- and post-drug experiment, the von Frey monofilament was conducted on days 7, 14, and 21 after drug or vehicle administration. The degree of hyperalgesia was expressed as the difference between the probability of the hyperalgesia response of the right and left paw for each animal.

Data analysis and statistics
----------------------------

All numerical data are presented as the mean ± S.E.M. Statistical significance was determined as P \< 0.05 using the student's paired *t*-test and n refers to the number of neurons studied.

Abbreviations
=============

ADAM, A Disintegrin and A Metalloprotease; CNS, Central Nervous System; CCI, Sciatic Nerve Chronic Constriction Injury Model; DRG, Dorsal Root Ganglia; DAPT, N-\[N-(3,5-difluorophenacetyl)-L-alanyl\]-S-phenylglycine t-butyl ester; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; MWT, Mechanical Withdrawal Threshold; NICD, Notch intracellular domain Notch; NS, Normal Saline; SNI, Spared Nerve Injury Model.
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